Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome

BACKGROUND: Although the clinical benefit of imatinib adjuvant therapy for high-risk patients with gastrointestinal stromal tumor (GIST) has been proven, the recurrence rate still remains high. This study aimed to sub-divide high-risk GIST patients with some “very high-risk” factors for more precise...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Wen-Yi, Xu, Jia, Wang, Ming, Zhang, Zi-Zhen, Tu, Lin, Wang, Chao-Jie, Cao, Hui, Zhang, Zhi-Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4057930/
https://www.ncbi.nlm.nih.gov/pubmed/24906683
http://dx.doi.org/10.1186/1471-230X-14-105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4057930/
https://www.ncbi.nlm.nih.gov/pubmed/24906683
http://dx.doi.org/10.1186/1471-230X-14-105

Ejemplares similares